---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-008475"
form_type: "8-K"
ticker: "BIXT"
cik: "0001445815"
company_name: "BIOXYTRAN, INC"
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:35:14.300772+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Bioxytran's ProLectin-M achieves 90% Day-5 viral clearance in Phase 1b/2a COVID-19 study

## Summary
- Phase 1b/2a trial: 39 patients; highest dose 16,800 mg/day showed 90% Day-5 viral clearance vs 20% placebo (p=0.001).
- 90% of highest-dose cohort had ≥2-point improvement on WHO Ordinal Scale by Day 5 vs 20% placebo.
- No serious adverse events, no treatment-related discontinuations; favorable safety profile across all doses.
- ProLectin-M targets galectins to block viral entry; potential broad-range antiviral beyond COVID-19.
- Company plans larger studies to evaluate ProLectin-M as first-line oral antiviral therapy.

## SEC filing metadata
- accession: 0001493152-26-008475
- form_type: 8-K
- ticker: BIXT
- cik: 0001445815
- company_name: BIOXYTRAN, INC
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445815/000149315226008475/0001493152-26-008475-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445815/000149315226008475/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-008475
- JSON: https://secwatch.observer/filing/0001493152-26-008475.json
- Plain text: https://secwatch.observer/filing/0001493152-26-008475.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.